LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical...
School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine nasal spray) 2...
-- Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to...
MADRID, Spain and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage...
PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:...
BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
LOS ANGELES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and...
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. fka/ E-Buy Home, Inc. (OTC: EBYH). Strainsforpains, Inc. is redefining...
Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under...
- Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics,...
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of...
TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare technologies Inc. (NASDAQ: MRM) (“MEDIROM”), a health technology and holistic healthcare...
- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group...
--128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants-- --150 maximum participant enrollment projected by...
– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters...
Ms. Colacot brings over 25 years of quality leadership experience across the biopharmaceutical and medical device industriesNEW YORK, Jan. 21,...
ELYXYB®, a rapid onset and ready-to-use formulation of Celecoxib, delivers a first line non-opioid therapeutic alternative to habit-forming opioids and...
National Distributor Eager To Begin Sales & Marketing Of Vascular Compression Therapy SolutionsToronto, Ontario--(Newsfile Corp. - January 21, 2025) -...
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Report on how AI is redefining market landscape - The global noise detection and...
VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a...